C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3016% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
C4 Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $98.86M, down 11.5% year over year. For fiscal 2025 it was $104.24M, down 5.8% from the year before. The highest annual figure on record is $117.84M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.24M | -5.8% |
| FY2024 | Dec 31, 2024 | $110.64M | -6.0% |
| FY2023 | Dec 31, 2023 | $117.71M | -0.1% |
| FY2022 | Dec 31, 2022 | $117.84M | +24.5% |
| FY2021 | Dec 31, 2021 | $94.67M | +20.7% |
| FY2020 | Dec 31, 2020 | $78.44M | +63.2% |
| FY2019 | Dec 31, 2019 | $48.06M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.80M | -4.6% |
| Q2 FY2026 | Jun 30, 2026 | $24.47M | -6.6% |
| Q1 FY2026 | Mar 31, 2026 | $24.61M | -9.1% |
| Q4 FY2025 | Dec 31, 2025 | $24.98M | -23.2% |
| Q3 FY2025 | Sep 30, 2025 | $25.99M | -18.4% |
| Q2 FY2025 | Jun 30, 2025 | $26.20M | +10.3% |
| Q1 FY2025 | Mar 31, 2025 | $27.07M | +20.1% |
| Q4 FY2024 | Dec 31, 2024 | $32.51M | +7.0% |
| Q3 FY2024 | Sep 30, 2024 | $31.84M | +12.3% |
| Q2 FY2024 | Jun 30, 2024 | $23.75M | -20.6% |
| Q1 FY2024 | Mar 31, 2024 | $22.53M | -22.4% |
| Q4 FY2023 | Dec 31, 2023 | $30.39M | -0.9% |
| Q3 FY2023 | Sep 30, 2023 | $28.35M | -4.4% |
| Q2 FY2023 | Jun 30, 2023 | $29.93M | -4.5% |
| Q1 FY2023 | Mar 31, 2023 | $29.04M | +10.8% |
| Q4 FY2022 | Dec 31, 2022 | $30.65M | +15.4% |
| Q3 FY2022 | Sep 30, 2022 | $29.66M | +22.1% |
| Q2 FY2022 | Jun 30, 2022 | $31.32M | +34.5% |
| Q1 FY2022 | Mar 31, 2022 | $26.20M | +27.7% |
| Q4 FY2021 | Dec 31, 2021 | $26.55M | +29.9% |
| Q3 FY2021 | Sep 30, 2021 | $24.30M | +1.5% |
| Q2 FY2021 | Jun 30, 2021 | $23.29M | +31.1% |
| Q1 FY2021 | Mar 31, 2021 | $20.53M | +25.8% |
| Q4 FY2020 | Dec 31, 2020 | $20.43M | +27.6% |
| Q3 FY2020 | Sep 30, 2020 | $23.94M | +84.9% |
| Q2 FY2020 | Jun 30, 2020 | $17.76M | – |
| Q1 FY2020 | Mar 31, 2020 | $16.31M | – |
| Q4 FY2019 | Dec 31, 2019 | $16.02M | – |
| Q3 FY2019 | Sep 30, 2019 | $12.95M | – |
See a number that looks wrong?